Amy Gamber, VP of Manufacturing at Atara Biotherapeutics, dives into the world of allogeneic T-cell immunotherapy, highlighting the groundbreaking Tabulecosel treatment. She discusses the complexities of scaling manufacturing, addressing donor variability, and efficient inventory management. The conversation reveals the vital role of data analytics in enhancing product quality, continuous quality monitoring, and predictive modeling. Gamber also explores the future of cell therapy manufacturing, emphasizing the potential of AI and the importance of standardizing data for improved patient outcomes.
